Tesidolumab clinical trials
Also written LFG316.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses tesidolumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LFG316
- 9
Studies by the year they started
9 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 4 |
| 2015 | 2 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Immunoglobulins, Intravenous (1) · Immunoglobulin G (1) · CLG561 (1)
Studies
Open first, then newest update. How each study uses tesidolumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 2Novartis PharmaceuticalsNCT02534909Written as LFG316
- Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,CompletedPhase 2Novartis PharmaceuticalsNCT01526889Written as LFG316
- Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)CompletedPhase 2Novartis PharmaceuticalsNCT01527500Written as LFG316
- Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) PatientsTerminatedPhase 2Novartis PharmaceuticalsNCT02763644Written as LFG316 active drug
- Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)CompletedPhase 2Novartis PharmaceuticalsNCT01535950Written as LFG316
- Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).TerminatedPhase 2Novartis PharmaceuticalsNCT01624636Written as LFG316
- Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316CompletedPhase 1Novartis PharmaceuticalsNCT02878616Written as LFG316
- CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)CompletedPhase 2Alcon ResearchNCT02515942Written as LFG316
- Intravitreal LFG316 in Patients With Advanced Age-related Macular DegenerationCompletedPhase 1Novartis PharmaceuticalsNCT01255462Written as LFG316
Codes
What other systems call tesidolumab · ClinicalTrials.gg INT001714
- MeSH (NLM) C000719367tesidolumabOne source NLM
- UNII (FDA) 3FO6689MSDTESIDOLUMABConfirmed FDA, NLM
- NCI Thesaurus C129315TesidolumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719367 | tesidolumab | One source NLM |
| UNII (FDA) | 3FO6689MSD | TESIDOLUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C129315 | Tesidolumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.